overall survival – Medxy AI

HPV Positivity in Keratinizing Nasopharyngeal Carcinoma: Implications for Prognosis and Clinical Practice

By MedXY 10/20/2026

HPV-positive keratinizing nasopharyngeal carcinoma demonstrates significantly improved overall survival compared to HPV-negative cases, underscoring the prognostic and clinical relevance of HPV testing in NPC management.

$CAR T-Cell Therapy Revolutionizes Outcomes in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: Insights from Pooled REPRIME-FIL and CART-SIE Analyses$

Hematology-Oncology news Oncology

CAR T-Cell Therapy Revolutionizes Outcomes in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: Insights from Pooled REPRIME-FIL and CART-SIE Analyses

By MedXY 10/01/2026

A pooled analysis of REPRIME-FIL and CART-SIE studies shows CAR T-cell therapy significantly improves overall survival in relapsed/refractory primary mediastinal B-cell lymphoma compared to traditional salvage treatments including ASCT.

Hematology-Oncology news

Advancing Treatment in De Novo BCR::ABL1+ Acute Myeloid Leukemia: The Impact of Combining Intensive Chemotherapy with Tyrosine Kinase Inhibitors

By MedXY 09/24/2026

The addition of tyrosine kinase inhibitors to intensive chemotherapy markedly improves remission rates and overall survival in patients with de novo BCR::ABL1+ acute myeloid leukemia, suggesting a new standard of care approach.

news Oncology Otorhinolaryngology

Lymphovascular Invasion as an Independent Prognostic Marker in Laryngeal Squamous Cell Carcinoma: Insights from a National Cohort Study

By MedXY 09/23/2026

Lymphovascular invasion independently predicts worse overall survival in surgically treated laryngeal squamous cell carcinoma, influencing postoperative risk stratification and adjuvant therapy decisions.

Hematology-Oncology news

Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study

By MedXY 09/13/2026

This study evaluates how the number and positivity of lymph nodes affect survival outcomes in over 2,000 patients with stage I–III favorable histology Wilms tumor, underscoring the need for standardized lymph node sampling in surgical staging.

Hematology-Oncology news Oncology

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

By MedXY 08/26/2026

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients.

Dermatology news Oncology

Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial

By MedXY 08/13/2026

The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression-free survival endpoint.

Hematology-Oncology news Oncology

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

By MedXY 06/07/2026

Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.

Hematology-Oncology news Oncology

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors

By MedXY 05/09/2026

A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast cancer.

General Surgery news Oncology

Adequate Lymph Node Dissection May Carry a Survival Signal in Intrahepatic Cholangiocarcinoma

By MedXY 04/20/2026

An updated meta-analysis suggests lymph node dissection in intrahepatic cholangiocarcinoma may improve survival when it is truly adequate, especially when at least six nodes are retrieved and confounding is reduced.

Clinical Updates news Oncology Otorhinolaryngology

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

By MedXY 03/20/2026

This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.

$Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4$

Hematology-Oncology news

Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4

By MedXY 02/19/2026

The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse, marking a potential shift in the treatment paradigm.

General Surgery news Oncology

Systematic Complication Management Boosts Long-Term Survival in Pancreatic Cancer: Insights from the PORSCH Trial

By MedXY 02/16/2026

A post-hoc analysis of the nationwide PORSCH trial reveals that algorithm-based care for early recognition and management of postoperative complications significantly improves long-term overall survival in patients undergoing pancreatic resection for cancer, particularly those with pancreatic ductal adenocarcinoma.

news Oncology Otorhinolaryngology

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

By MedXY 01/30/2026

A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA clearance.

news Oncology Respiratory

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial

By MedXY 01/09/2026

The final analysis of the Phase III ALEX trial confirms alectinib's superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the first-line standard of care for ALK-positive advanced non-small cell lung cancer.

news Oncology

Distant Disease‑Free Survival Is a Reliable Surrogate for Overall Survival in Most Neoadjuvant Early Breast Cancer Trials — but Not All Subtypes

By MedXY 11/30/2025

A pooled individual‑patient analysis of 11 neoadjuvant RCTs (12,247 patients) finds distant disease‑free survival (DDFS) strongly predicts overall survival (OS) trial‑level effects overall (R2trial=0.91), with weakened surrogacy in hormone‑receptor‑positive subtypes.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results$

Hematology-Oncology news

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results

By MedXY 11/04/2025

The DREAMM-7 phase 3 trial shows that belantamab mafodotin combined with bortezomib and dexamethasone produces early, sustained, and statistically significant overall survival and deep, durable responses versus daratumumab-based therapy in relapsed/refractory multiple myeloma.

news Oncology Urology

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains from intensified therapy.

Gastroenterology news Oncology

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

By MedXY 10/29/2025

The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.

Gastroenterology news Oncology

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival

By MedXY 10/28/2025

This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need for better surrogate markers in clinical trials.